A peptide COA labeled “sterility” needs a method check. Compendial sterility testing under USP chapter 71 and a PCR microbial screen are different evidence. A PCR result can report the outcome of a useful molecular screen, but its heading alone does not establish a USP 71 test. Preserve the method and its scope whenever you summarize the certificate.
This article concerns research-use-only materials and laboratory documentation. It provides no dosing or medical advice. Open the full report in the COA library, and use the COA checker to inspect the issuing laboratory's verification evidence.
Three questions that often get collapsed into one
Sterility testing, microbial screening and endotoxin testing ask different questions. A growth-based sterility test looks for microbial growth under the specified test conditions. A molecular microbial screen examines specified genetic targets. An endotoxin assay measures bacterial endotoxin activity. Neither the method names nor their results should be exchanged in a vendor summary.
| Report wording | Evidence to look for | Faithful summary |
|---|---|---|
| USP 71 sterility test | Compendial method, incubation, suitability and result | Result under the stated USP 71 procedure |
| Sterility (PCR) | Molecular method, target scope, controls and result | PCR microbial screen result |
| Microbial count or limits | Named count or organism test, unit and criterion | Result for that specified microbial test |
| Endotoxin | Named endotoxin assay, EU unit and threshold | Separate endotoxin finding |
A broad statement such as “free of contamination” hides those differences. A research record is more useful when it states the exact question each test addressed.
What USP 71 sterility testing means
USP chapter 71, Sterility Tests, is the compendial reference to recognize. In a growth-based test, the sample is examined in culture media under defined conditions. Membrane filtration and direct inoculation are established approaches. Method suitability matters because material in the sample can inhibit microbial growth and obscure contamination.
Pacific BioLabs' description of USP 71 testing explains the use of two media, suitability testing and a fourteen-day incubation. USP's chapter 1071 introduction also explicitly distinguishes rapid approaches from the growth-based test with at least fourteen days of incubation. These references help identify the scope behind a report's method line.
For a reader, the useful questions are documentary: does the report name USP 71, identify the procedure, and provide a result traceable to the submitted sample? If the certificate gives only a generic “sterility pass,” request the issuer's method description. Do not add incubation details that are absent from the report or supporting documentation.
A result applies to the tested sample under the stated conditions. A vendor's lot-wide quality program involves sampling and manufacturing controls beyond the certificate page. Keep the submitted sample count visible when it is supplied, especially when comparing reports from different batches.
What a PCR microbial screen means
PCR-based testing examines microbial nucleic-acid targets through an amplification-based workflow. Its interpretation depends on target coverage, extraction, controls, sample interference and the laboratory's validation. A report should identify the screen rather than letting the word “sterility” replace that information.
Target coverage is a practical question: which microorganisms or groups could this method detect? A negative result is bounded by those targets and the method's sensitivity. The report also needs a basis for interpreting genetic material in relation to viable organisms; DNA detection and growth are different measurements. Promega's viability-PCR technical manual explains why ordinary PCR does not inherently distinguish live from dead cells. Ask how the issuing laboratory validates that interpretation for its own screen.
ILS currently describes its rapid screen as a DNA-based microarray platform on its laboratory FAQ. The reviewed ILS certificates in ZC Labs' archive print “Sterility (PCR).” Preserve the wording of the individual report, then use the issuer's method documentation to clarify the workflow. A newer service-page description should not silently rewrite the method on an older certificate.
Freedom Diagnostics' service page also lists “Sterility (PCR)” as a microbial contamination screen. That is useful primary-source confirmation of the label's intended scope. It should remain a microbial screen in editorial copy unless additional, sample-relevant validation supports a different claim.
Microbial enumeration is another distinct result
Some certificates provide counts or specified-organism results rather than a sterility conclusion. A count can use colony-forming units relative to a mass or volume. A specified-organism test asks whether its named target is found under the method. Those outputs require their own units and acceptance criteria.
The USP chapter 61 preview identifies microbial enumeration as a test family for nonsterile products. It is a useful reminder to read a count as a count. “Below the count limit,” “target not detected” and “no growth in a sterility test” are different statements, even when a vendor places them under the same microbiology heading.
When comparing reports, write down the actual assay, result and denominator. If one document supplies a PCR screen and another supplies a microbial count, retain both descriptions. Reducing them to a shared “clean” checkbox loses the evidence needed to choose material for a defined research protocol.
What PeptidePrices found in eight archives
The following September 25, 2026 snapshot uses public certificate records and retained verification evidence. The combined microbial/sterility column counts each record once even if it carries both labels. It does not count USP 71 tests, because a generic label cannot establish that method.
| Vendor | PeptidePrices issuer-check scope | Microbial or sterility evidence |
|---|---|---|
| Puratek Peptides | 42 of 42 reports matched official records | 34 carry sterility-labeled panels; retain the report's actual method |
| ZC Labs | 69 of 70 certificates matched | 23 of 24 ILS reports include the PCR screen |
| Rebirth Labs | All 119 public reports issuer matched | 46 public records have extractable microbial PCR coverage |
| Modern Research Peptides | 124 verified downloadable reports | 36 have microbial PCR results |
| Glacier Aminos | 245 exact issuer matches; 25 documentary-only records | 123 of 270 public records carry an extractable microbial or sterility label |
| Refined BioLabs | All 25 public records issuer verified | 25 carry a sterility label |
| Validated Peptides | All 17 public reports issuer matched | 12 carry a sterility label |
| IDUN Peptides | All 48 public records issuer verified | 26 carry a microbial or sterility label |
ZC's reviewed archive has 24 ILS and 46 Freedom certificates. Its 23 ILS PCR screens are a defined subset with a known method label. Modern Research Peptides' 36 PCR results are another directly described subset. These are stronger educational examples than assigning a compendial sterility claim to every certificate that happens to contain the word “sterility.”
Glacier's public set deliberately preserves documentary-only records. Its 123-panel figure is therefore a coverage count across the public set, not a count of 123 issuer-verified microbiology findings. The distinction remains useful even where a retained report contains clear analytical results.
Compare laboratories at the report level
The aggregate audit detects microbial or sterility labels on 388 of 698 ILS records, 458 of 607 Kovera records and 276 of 2,120 Freedom records. These totals include historical material and depend on what has been transcribed or extracted. They describe documented panel coverage, not the rate of contamination or the number of compendial sterility tests.
Use the ILS Laboratories, Kovera Labs and Freedom Diagnostics profiles to find issuer context. Then return to the selected certificate. A laboratory can offer several methods, and a vendor can order different panels for different samples.
Sample stage and batch linkage are essential
A bulk raw-material report describes material before later filling and packaging. If the research question concerns finished vials, inspect evidence for those submitted units. The sample description, lot and vial count establish the test's scope more clearly than the vendor's general testing policy.
For BPC-157, MOTS-c and GLP-3R, follow the exact listing's certificate and compare strength and unit as well as compound. An earlier report can remain valid historical evidence while a different batch requires its own documentation. An issuer match verifies the report relationship; it does not reconstruct custody of a later-delivered vial.
Also check whether the complete microbial result is on a second page. A front-page purity summary can omit the method, targets or interpretation needed here. Keep the full report and the issuer response together so the next reviewer sees the same evidence.
Read the remaining panels separately
A microbial result does not supply a peptide identity, a measured fill amount, an elemental-impurity result or an endotoxin result. Continue with the core three-panel test, endotoxin and LAL testing, and ICP-MS heavy-metal testing. The complete COA guide explains verification states and the snapshot method.
For your research record, copy the assay wording exactly, preserve the target scope and result, and state whether the issuer supplied a full record or only existence confirmation. That produces a precise microbial-testing claim that another reader can check.